A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. (Q41122864)

27 September 2017

A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. (English)

1 reference

27 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Saikat Santra

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Guirish A Solanki

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Luying Pan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Joseph Muenzer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Zheng Fan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Suresh Vijayaraghavan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Victor Perry

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Mary Ann Mascelli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Nan Wang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Kenneth Sciarappa

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Ann J Barbier

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

2 April 2015

1 reference

27 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

73-81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25834948%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/gim.2015.36

8 June 2020

exact match

0 references

cites work

The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

Behaviour in mucopolysaccharide disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

Multidisciplinary management of Hunter syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

Properties of permuted-block randomization in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2015.36

A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25834948

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25834948